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Available online 12 March 2016Fingolimod (FTY720) is a new generation oral treatment for multiple sclerosis (MS). So far, FTY720 was mainly
considered to target trafﬁcking of immune cells but not brain cells such as neurons. Herein, we analyzed
FTY720's potential to directly alter neuronal function. In CNS neurons, we identiﬁed a FTY720 governed gene
expression response. FTY720 upregulated immediate early genes (IEGs) encoding for neuronal activity associated
transcription factors such as c-Fos, FosB, Egr1 and Egr2 and induced actin cytoskeleton associated genes (actin
isoforms, tropomyosin, calponin). Stimulation of primary neurons with FTY720 enhanced neurite growth and
altered growth cone morphology. In accordance, FTY720 enhanced axon regeneration in mice upon facial
nerve axotomy. We identiﬁed components of a FTY720 engaged signaling cascade including S1P receptors,
G12/13 G-proteins, RhoA-GTPases and the transcription factors SRF/MRTF.
In summary, we uncovered a broader cellular and therapeutic operation mode of FTY720, suggesting beneﬁcial
FTY720 effects also on CNS neurons during MS therapy and for treatment of other neurodegenerative diseases
requiring neuroprotective and neurorestorative processes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Neurodegeneration1. Introduction
Fingolimod (FTY720) is a novel drug for patientswith relapsing remit-
ting MS (Brinkmann et al., 2010; Pelletier and Haﬂer, 2012; Sanford,
2014). Mechanistically, FTY720 exerts its beneﬁcial function through
preventing CNS entry of auto-immune lymphocytes (Brinkmann et al.,
2010; Brunkhorst et al., 2014; Chun and Hartung, 2010). FTY720 as well
as its analog sphingosine are phosphorylated in vivo by sphingosine ki-
nases (SphK) to produce the biologically active molecules, sphingosine-
1-phosphate (S1P) or FTY720-phosphate (FTY720-P). Similar to S1P,
active FTY720 engages several G protein coupled S1P receptors. Besides
its peripheral immune modulatory functions, FTY720 was attributed
beneﬁcial effects directly on the CNS (Ingwersen et al., 2012). FTY720
has a neuroprotective impact in various murine disease models
(Brunkhorst et al., 2014) including neuroinﬂammation associated with
axonal injury (Lee et al., 2009), ischemia (Hasegawa et al., 2010; Wei
et al., 2011), prion (Moon et al., 2013) or β-amyloid toxicity (Takasugi
et al., 2013), exitotoxicity (Deogracias et al., 2012; Di Menna et al.,
2013) and Rett syndrome (Deogracias et al., 2012). In the latter two
reports, brain derived neurotrophic factor (BDNF) was identiﬁed as
mediator of FTY720 activity (Deogracias et al., 2012; Di Menna. This is an open access article underet al., 2013). FTY720 modulates de- and/or remyelination in MS
mouse models, although the exact cellular target (e.g. neurons or
glia) of FTY720 action is difﬁcult to decipher (Blanc et al., 2014;
Choi et al., 2011; Kim et al., 2011; Papadopoulos et al., 2010). Recent
data suggest an axonoprotective FTY720 function (Slowik et al.,
2014). Nevertheless, data of FTY720 action on neurons are sparse
and the impact of FTY720 on neurons is just at the beginning of
being analyzed in depth. Spiegel and colleagues recently reported
that FTY720 inhibits speciﬁc histone deacetylases (HDACs) in neurons
(Hait et al., 2014). Such epigenetic alterations suggest that FTY720
mediates distinct neuronal gene expression programs, potentially
involving the gene regulator CREB (Deogracias et al., 2012). However,
detailed molecular and cellular insights on FTY720's mechanism of
modulating such neuronal functions are currently not available. In
astrocytes (Cui et al., 2014; Osinde et al., 2007) or Schwann cells
(Heinen et al., 2015), FTY720 was reported to modulate speciﬁc gene
expression programs.
In this study we report that FTY720 elicits a neuronal gene expres-
sion response, resulting in induction of neuronal activity connected
genes including the immediate early genes (IEG) c-Fos, FosB, Bdnf, Egr1
and Egr2. In addition, FTY720 induced genes encoding for components
of the actin cytoskeleton. In agreement, FTY720 modulated the mor-
phology of actin-rich neuronal growth cones and stimulated neurite
growth in vitro aswell as axonal regeneration in vivo. FTY720's potentialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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receptor-G12/13-RhoA dependent signaling cascade and the transcrip-
tion factor serum response factor (SRF), a neuroprotective gene regula-
tor. SRF is an established neuronal activity induced transcription factor
conveying a neuronal IEG response (Knoll and Nordheim, 2009;
Ramanan et al., 2005). For regulation of IEGs, MAP kinase signaling
stimulates an SRF interaction with cofactors of the TCF family including
Elk-1 (Knoll and Nordheim, 2009; Posern and Treisman, 2006). Besides
IEGs, SRF is intimately connected with the regulation of cellular actin
dynamics and, in turn, SRF activity is also adjusted by the cellular actin
equilibrium and Rho-GTPases (Olson and Nordheim, 2010). Several
SRF target genes encode for actin isoforms (e.g. Acta, Actb) and actin
binding proteins (ABPs) such as tropomyosin and calponin. A further
ABP regulated by SRF is the actin severing factor coﬁlin (Alberti et al.,
2005; Beck et al., 2012), known to modulate neuronal actin dynamics
(Flynn et al., 2012). Here, SRF teams upwith a second class of cofactors,
myocardin related transcription factors (MRTFs), whose activity is
adjusted by Rho-GTPases and changes in the cellular G- to F-actin
ratio (Olson and Nordheim, 2010). SRF-deﬁcient neurons display
altered actin dynamics and aberrant growth cone structures. In addi-
tion, SRF stimulates various aspects of neuronal cell motility including
axon growth (Knoll and Nordheim, 2009; Olson and Nordheim, 2010)
and PNS axon regeneration (Stern et al., 2013; Stern and Knoll, 2014).
SRF deﬁciency also affects myelin de- and regeneration in mouse
models of demyelination (Anastasiadou et al., 2015).
Herein we present a direct FTY720 impact on neurons, suggesting
that FTY720 medication impinges on both immune cell as well as
neuronal function. This ﬁnding is of potential interest not only for MS
therapy but also for the therapy of other neurological diseases aiming
at restoration of neuronal function.
2. Materials and methods
2.1. Neuronal cell culture
We used for all neuronal cell cultures C57BL/6 mice. Cerebellar
cultures derived from postnatal day (P) four to ﬁve (P4–P5) mice
were incubated in NMEM/B27 medium as described previously (Knoll
et al., 2006). Adult DRG neurons were harvested from 6 to 8 week old
mice and were cultured for 24 h with or without NGF (50 ng/ml;
Peprotech) as indicated. For biochemical and qPCR analysis, cere-
bellar neurons (3 × 106) were cultured on poly-L-lysine (10 μg/ml;
Sigma) and laminin (2 μg/ml; Gibco) coated 35 mm dishes. For
immunocytochemisty, cerebellar (2.5 × 104) or DRG (5 × 103) neurons
were plated on poly-L-lysine (100 μg/ml) and laminin (5 μg/ml) coated
coverslips (13 mm).
For qPCR experiments, cerebellar neurons were treated with 2 μM
FTY720 (Novartis, Switzerland; stock: 10 mM in DMSO) after 2 div
(days in vitro) for 1, 8 or 24 h. BDNF (Peprotech) was applied to the
culture medium of cerebellar neurons, grown for 2 div, at 10 ng/ml
also for 1, 8 or 24 h. Diethyl fumarate (Sigma-Aldrich) was used at a
ﬁnal concentration of 10 μM. For neurite growth experiments (e.g.
Fig. 3), neurons were grown in culture for a total duration of 24 h.
For Rho inhibition, we used the fusion toxin C2IN-C3lim at
300 ng/ml together with C2IIα at 600 ng/ml for 24 h (Barth et al.,
1998). C2IN-C3lim/C2IIα was applied to cultures at 2 div. To ensure
inhibition by C2IN-C3lim/C2IIα over the 24 h period, substances were
added again into the medium 8 h after the ﬁrst application. To deliver
the Lsc-RGS (Moepps et al., 2008), MALΔNΔB1 (Miralles et al., 2003)
or coﬁlin-GFP (Beck et al., 2012) expression vectors into neurons, we
used nucleofection (Mirus) with 3 μg plasmid DNA for 4 × 106 cells.
JTE-013 (Tocris), NIBR-0213 (Glixx Laboratories) and TY52156 (Tocris)
were dissolved in DMSO and pre-incubated for 30 mins at 10 μM, 1 μM
and 1 μM, respectively for gene expression studies. For neurite growth,
inhibitors were applied for the entire duration of the experiment at
1 μM (JTE-013), 0.1 μM (NIBR-0213) and 0.1 μM (TY52156). S1P wasdissolved in MeOH and applied at 1 μM. All inhibitors were added
already 30 min before FTY720 or S1P administration to cultures.
For the downregulation of SRF and CREB via siRNA, we used the
ON-TARGETplus SMARTpool siRNA (Dharmacon), L-050116-01 and
L-040959-01, respectively. As control siRNA, we used the AllStars
Neg. Control siRNA (Qiagen). All siRNAs were delivered into the neurons
by nucleofection of 1 μMsiRNA solution. Cells were kept 3 days in culture
prior to stimulation with FTY720.
All antagonists and siRNAs are summarized in Table 1.
2.2. Facial nerve transection
Facial nerve transection was performed as described previously
(Raivich et al., 2004; Stern et al., 2013). Adult C57BL/6 mice of either
sex (approx. 12 weeks old) were anesthetized by inhalation of
isoﬂurane, a skin incision was made behind the left ear, and the facial
nerve was exposed. Afterwards, the nerve was transected with
microscissors 2 mm posterior to the foramen stylomastoideum. The
contralateral nerve was left intact and responses in this facial nucleus
served as intra-animal control. Absence of eye-lid closure and whisker
movement proved successful nerve transection. FTY720 (1 mg/kg
body weight) or the same volume DMSO was i.p. injected every second
day, starting one day after injury. Similar FTY720 concentrations were
used by others (Choi et al., 2011; Hait et al., 2014; Kim et al., 2011).
Regeneration of the facial nerve was quantiﬁed by retrograde axonal
tracing with ﬂuorogold (FG; Fluorochrome). For this, 4 × 1 μl of FG
(4% in H2O) was injected with a Hamilton syringe at multiple positions
in each whisker pad 15 d after injury. After another 3 d, brains were
dissected. FG-positive neurons of all sections of both facial nuclei per
each animal were evaluated before immunohistological staining. Before
and after facial nerve transection, animals were housed in groups in
standard cages. Mice were maintained under speciﬁc pathogen-free
conditions with free access to food and water in the animal facility
(12-h light–dark cycle) of University of Ulm. All experiments were in
accordance with institutional guidelines and German animal protection
laws andwere approved by the regional government authority (Number:
1232; Regierungspräsidium Tübingen, Germany).
2.3. Organotypic cerebellar cell culture
Cerebellar slices (350 μm) of P5 C57BL/6 wildtype mice were
prepared with a tissue chopper (Bachhofer, Reutlingen, Germany).
Subsequently, four slices were arranged on the membrane of a Millicell
cell culture insert (PICMO3050;Millipore) placed in onewell of a 6-well
plate with 1 ml of NMEM/B27 medium. The next day, slices were
stimulated by adding DMSO, FTY720 (2 μM) or BDNF (10 ng/ml) in
the culture medium for 2 h, 8 h or 24 h as indicated in Fig. 2.
2.4. Immunocytochemisty
Cells were ﬁxed for 15min in 4% PFA/5% sucrose/PBS, permeabilized
for 5 min in 0.1% Triton-X-100/PBS and blocked for 30min in 2% BSA/
PBS. The primary antibody against rabbit anti class III β-tubulin
(1:1000; Covance; Cat. No. PRB-435P) was incubated overnight at 4 °C.
The primary antibody was detected with a goat Alexa 488 conjugated
secondary antibody (1:1500; Molecular Probes; Cat. No. A-11008).
F-actinwas stainedwith Texas Red-X Phalloidin (1:70;Molecular Probes)
in the secondary antibody solution. Phalloidin labels F-actin in all cells, not
only neurons, present in a culture and was used for quantiﬁcation of the
total number of neurons (βIII tubulin positive) in the cerebellar cultures
(Supplementary Fig. 1).
2.5. Immunohistochemistry
Organotypic cultures were ﬁxedwith 4% paraformaldehyde (PFA) in
PBS for 1 h at 4 °C, followed by preparation of 7 μm parafﬁn microtome
c-
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Table 1
Summary of reagents used.
Agent Target Supplier/company Concentration Application duration Application time-point
C2IN‐C3lim RhoA-GTPases Holger Barth
Ulm University
300 ng/ml 1 div After 2 div
Lsc-RGS Gα12/13 Barbara Möpps
Ulm University
Electroporation of 3 μg plasmid 2 div Immediately when plating neurons
JTE-013 S1PR2 receptor Tocris
Cat. No. 2392
10 μM (qPCR)
1 μM (neurite growth)
– 30 min (qPCR)
– 1 div (neurite growth)
– 30 min before FTY stimulation (qPCR)
– Immediately after plating (neurite growth)
NIBR-0213 S1PR1 receptor Glixx Laboratories
Cat. No. GLXC-02221
1 μM (qPCR)
0.1 μM (neurite growth)
– 30 min (qPCR)
– 1 div (neurite growth)
– 30 min before FTY stimulation (qPCR)
– Immediately after plating (neurite growth)
TY52156 S1PR3 receptor Tocris
Cat. No. 5328
1 μM (qPCR)
0.1 μM (neurite growth)
– 30 min (qPCR)
– 1 div (neurite growth)
– 30 min before FTY stimulation (qPCR)
– Immediately after plating (neurite growth)
siSrf Mouse SrfmRNA Dharmacon
Cat. No.
L-050116-01
Electroporation of 1 μM siRNA 3 div – Immediately after plating
siCreb Mouse CrebmRNA Dharmacon
Cat. No.
L-040959-01
Electroporation of 1 μM siRNA 3 div – Immediately after plating
Control siRNA No mRNA target Qiagen Cat. No.
SI03650318
Electroporation of 1 μM siRNA 3 div – Immediately after plating
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antibodies: mouse anti-NeuN (1:500; Millipore; Cat. No. MAB377) and
rabbit anti-c-Fos (1:10,000; Calbiochem; Cat. No. ABE457). Primary
antibodies were detected with goat anti-mouse or rabbit Alexa 488
(Cat. No. A-11008 or A-11001) and Alexa 546 (Cat. No. A-11003 or
A-11071) conjugated secondary antibodies (1:1500; all from
Molecular Probes).
Brains were dissected in ice-cold PBS and ﬁxed in 4% PFA for
3–4 days at 4 °C. Then, the tissue was dehydrated (2 × 70% EtOH,
2 × 90% EtOH, 2 × 100% EtOH, 3 × 100% Xylene, 3 × Parafﬁn; each
90min), embedded in parafﬁn in plastic holders, followed by preparation
of 5 μm parafﬁn microtome slices. After blocking with 2%BSA/PBS,
sections were labeled with primary antibodies including anti-ATF3
(rabbit, 1:500; Santa Cruz Biotechnology; Cat. No. sc-188), anti-
SMI-32 (mouse, 1:500; Millipore; Cat. No. NE1023), anti-FG (rabbit,
1:5000, Millipore; Cat. No AB153), anti-IBA1 (rabbit, 1:1000, Wako;
Cat. No. 019-19741), anti-S100 (mouse, 1:1000; Abcam; Cat. No.
Ab4066), anti-MBP (mouse, 1:2000; Covance; Cat. No. NE1018),
anti-nestin (mouse, 1:1000; Chemicon; Cat. No. MAB353), anti-
doublecortin (rabbit, 1:1000; Abcam; Cat. No Ab18723) and anti-GFAP
(mouse, 1:1000; Santa Cruz; Cat. No. sc-33673). Detection of primary
antibodies was performed using goat anti-mouse Biotin (1:500; Vector
Laboratories; Cat. No. BA-9200) or Alexa Fluor (1:500; Invitrogen;
see above) conjugated secondary antibodies and peroxidase-based
detection systems using the ABC complex (Vector Laboratories) and
DAB as substrate.
2.6. Biochemistry
Cells or brain slices were lysed in 100mMTris pH 7.8, 150mMNaCl,
1 mM EDTA, 1% Triton-X-100, 1× protease inhibitors (Roche) and 1×
PhosStop (Roche). Samples were resolved on 10% SDS-PAGE, followed
by transfer on PVDF membranes (Amersham). After 1 h of blocking,
ﬁrst antibodies were applied overnight at 4 °C: rabbit anti-CREB
(1:1000; Cell Signaling; Cat. No. 9197S), rabbit anti-P-CREB (1:1000;
Cell Signaling; Cat. No. 9198S), rat anti-SRF (1:250; kindly provided by
A. Nordheim, Tübingen University, Germany), mouse anti-GAPDH
(1:60,000; Acris; Cat. No. OTI2D9), rabbit anti-c-Fos (1:1000; Santa
Cruz; Cat. No. sc-52), rabbit anti-FosB (1:500; Santa Cruz; Cat. No: sc-
48), rabbit anti-Egr1 (1:500; Santa Cruz; Cat. No. sc-110), rabbit anti-
Coﬁlin (1:1000; Cell Signaling; Cat. No. 3312), rabbit anti-P-Coﬁlin (Serine
3; 1:1000; Cell Signaling; Cat. No. 3311) and rabbit anti-Egr2 (1:500;Covance; Cat. No. PRB-236P). Detection of ﬁrst antibodies involved
horseradish-peroxidase conjugated secondary antibodies (1:5000; Santa
Cruz Biotechnology) and the ECL Western Blotting Substrate (Pierce).
Membranes were exposed on X-ray ﬁlms (Fujiﬁlm) in a dark room and
developed in an Agfa ﬁlm processor (X-ray developer).
2.7. Quantitative real-time PCR (qPCR)
We isolated total RNA from P3-P5 postnatal cerebellar cell cultures
grown for 2 div with the RNeasy kit (Qiagen). Reverse transcription
was performed with 1 μg RNA using reverse transcriptase (Promega)
and random hexamers. We performed qPCR on a Light Cycler 480II
(Roche) with the Power PCR SYBR green PCR master mix (Takara).
The LC480 II Software detects this threshold cycle value (Ct value) for
each sample. The higher the Ct value, the lower the original cDNA
amount for a certain gene in the sample. In order to neutralize potential
variations in total mRNA amounts used for the cDNA synthesis, the Ct
values of the house keeping gene Gapdh (glycerinaldehyd-3-
phosphat- dehydrogenase) were used for normalization. The relative
mRNA expression values of the control sample (DMSO treated) were
set to 1.
Primer sequences:Primer Fwd primer sequence (5′ N 3′) Rev primer sequence (5′ N 3′)Fos CCT GCC CCT TCT CAA CGA C GCT CCA CGT TGC TGA TGC T
sB TAA TGT GCA GGA ACC GTC GG TGC CTT TTC CTC TTC AAG CTG
r1 GCC GAG CGA ACA ACC CTA T TCC ACC ATC GCC TTC TCA TT
r2 GTT GAC TGT CAC TCC AAG AAA TGG AGC GCA GCC CTG TAG GC
cta CAG CAA ACA GGA ATA CGA CGA A TGT GTG CTA GAG GCA GAG CAG
m1a CTG ATA AGA AGG CGG CGG TCT TTT GCA GTG ACA CCA GCTC
nn GAA GGT CAA TGA GTC AAC TCA GAA CCA TAC TTG GTA ATG GCT TTG A
gln GAT GTA GGC CGC CCA GAT C ATC ACA CCA TTC TTC AGC CAC A
dnf ACC ATA AGG ACG CGG ACT TG GAG TAG AGG AGG CTC CAA AGG C
cl2 CCC AAT GAG TAG GCT GGA GA TCT GGA CCC ATT CCT TCT TG
cl3 TGC CCT TGC TGT TCT TCT CT GTG GAA TCT TCC GGC TGT AG
cl9 GGC ACA GCA AGG GCT TGA GGA CAG GCA GCA ATC TGA AGAC2.8. Statistical analysis and quantiﬁcation
The exact numbers (n) of independent cell cultures or animals are
indicated in ﬁgure bars. For Fig. 1, the number of independent cell
cultures analyzed for all panels is provided in Fig. 1F. In Fig. 2A–D, one
culture was analyzed for each time-point. In Fig. 2E and F, organotypic
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the total number of growth cones, each marked by a circle, derived
from three independent cultures is provided. For Figs. 4 and 6, seven
animals were tested for each condition (control or FTY treated). In
Fig. 5, the total number of neurons, each marked by a circle, derived
from three independent cultures is provided. In Fig. 7, three to seven
animals were tested for each condition as indicated in the bar graphs.
For Fig. 8A, the number of independent cell cultures analyzed for all
panels is provided in the bar graph. For Fig. 8B–J, the number of indepen-
dent cell cultures analyzed for each panel is provided in Fig. 8B. In Fig. 8K,
L, the total number of neurons, each marked by a circle, derived from
three independent cultures is provided. For Fig. 9, the number of indepen-
dent cell cultures analyzed for each panel is provided in Fig. 9A. In
Fig. 10A, the number of independent cultures is presented in the bar
graph. For Fig. 10B–J, the number of independent cell cultures analyzed
for each panel is provided in Fig. 10B. For Fig. 10K–O, the total number
of growth cones, eachmarked by a circle, derived from three independent
cultures is provided.Fig. 1. FTY720 induces a neuronal gene expression response.Mouse cerebellar neurons were
indicated. BDNF application was included as a positive control for IEG induction. Subsequent
(c-Fos, FosB, Egr1, Egr2, Bdnf), genes encoding components of the actin cytoskeleton (Acta,
control, ﬁrst black bar) were set to 1 and fold induction is depicted. (A–D) FTY720 upregula
more effective in IEG induction. BDNF application achieved IEG induction already at 1 h. Die
upregulated by FTY720. In contrast, BDNF reduced mRNA abundance of Acta (E), Tpm1a (F
expression. (I) BdnfmRNA abundance was elevated by FTY720, but not BDNF or fumarate adm
Ccl3 (K) and Ccl9 (L) were downregulated by FTY720. Numbers in bars in (F) indicate the n
expressed as mean ± SD. Statistical signiﬁcance was calculated in relation to the non-stimulatFor growth conemorphology (≥100 growth cones/condition) and
quantiﬁcation of neurite length, pictures were analyzed using Zeiss
Axiovision software. Growth cone area was recognized by phalloidin
staining labeling the growth cone F-actin content. Here, the area tool
was used to mark the entire outline of each individual growth cone.
In order to exclude false positive signals not derived from growth
cones, a threshold was set to exclude objects b 5 μm2 and
N500 μm2. The total pixel number/growth cone area calculated by
the axiovision software was converted to μm2. For ﬁlopodia
number, the total number of ﬁlopodia of one growth cone was quan-
tiﬁed. Only ﬁlopodia N 1 μm were counted. For neurite length,
the maximal neurite length of an individual βIII tubulin neuron
was manually traced with the measure curve spline tool of the
Zeiss Axiovision software.
Statistical signiﬁcance was calculated using Prism6 software with
2way ANOVA multiple comparison tests with *, **, *** indicating
p ≤ 0.05, 0.01 and 0.001, respectively. All data show SD if not indicated
otherwise.stimulated with the oral MS drugs FTY720 or diethyl fumarate (“fumar.”) for time-points
ly, qPCR was performed to quantify mRNA abundance of several immediate early genes
Tpm1a, Cnn1 and Tagln) and CCL chemokines (Ccl2, Ccl3, Ccl9). Control values (DMSO
ted mRNA levels of all four IEGs tested. Overall, longer FTY720 application periods were
thyl fumarate failed to modulate IEG levels. (E–H) All four actin associated genes were
), Cnn (G) and Tagln (H). Fumarate had no obvious impact on actin cytoskeletal gene
inistration. (J–L) The CCL chemokine family member Ccl2 (J) was upregulated, whereas
umber of independent cell cultures analyzed for each gene depicted in (A–L). Data are
ed sample (ﬁrst black bar in each panel).
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3.1. FTY720 induces a neuronal gene expression response
In order to analyze FTY720's potential to elicit a neuronal gene
response, we used P3–P5 primary mouse cerebellar neurons (Fig. 1).
These cultures consist of more than 90% (90.5 ± 1.5%; N = 3) of βIII
tubulin positive neurons thereby reﬂecting almost exclusively neuronal
responses (Supplementary Fig. 1). Cultures were treated with FTY720
for 1, 8 or 24 h. We used FTY720 in its unphosphorylated form at
2 μM, a concentration similarly used by other reports (Hait et al.,
2014; Jackson et al., 2011; Takasugi et al., 2013). After cellular uptake,
FTY720 is phosphorylated by SphK2 to P-FTY720 in many cell types,
including neurons (Hait et al., 2014). We found robust Sphk2 mRNA
expression also in cerebellar neurons. Sphk2 mRNA levels were not
affected by FTY720 application (data not shown). In addition to
FTY720, diethyl fumarate was employed, a further oral MS drug (Fox
et al., 2014). We also included BDNF administration, known to elicit
neuronal gene expression (Meier et al., 2011). After three days in vitro
(div), cDNA prepared from cell cultures was subjected to qPCR allowing
for quantitation of mRNA abundance of several immediate early genes
(c-Fos, FosB, Egr1, Egr2, Bdnf). In order to analyze FTY720 induced
modulation of actin-based neuronal motility, we examined mRNA
abundance of genes encoding components of the actin cytoskeleton
such as the actin isoform Acta (actin alpha 1, skeletal muscle). In
addition, we analyzed ABPs of the calponin family, Cnn1 (calponin1)
and Tagln (transgelin), established regulators of actin-myosin interac-
tion and tropomyosin (Tpm1a), an ABP enhancing actin polymerization
and stabilizing actin ﬁlaments. Finally, we investigated whether FTY720
stimulates neuronal CCL chemokine abundance (Ccl2, Ccl3, Ccl9),
established mediators of a brain resident immune response (Bose and
Cho, 2013).
We observed that FTY720 administration resulted in a strong IEG
response of c-Fos (Fig. 1A), FosB (Fig. 1B), Egr1 (Fig. 1C) and Egr2
(Fig. 1D) with maximal mRNA induction peaking 8 h–24 h after
application. FTY720 application exceeded the well-known IEG inducer
BDNF in c-Fos and FosB upregulation (Fig. 1A, B). Besides these four
IEGs (Fig. 1A–D), FTY720 induced further IEGs including Cyr61, Egr3,
Npas4 and Nr4a1 (Supplementary Fig. 2). In contrast, FTY720 did not
alter Srf mRNA, SRF protein level or SRF phosphorylation (data not
shown). In addition, we observed that FTY720 – but not BDNF – induced
all actin cytoskeleton associated genes in a time dependent manner
(Fig. 1E–H). FTY720 also upregulated Bdnf mRNA abundance (Fig. 1I)
as reported before (Deogracias et al., 2012; Hait et al., 2014). Finally,
we observed that FTY720 modulated neuronal mRNA abundance of
CCL chemokines (Fig. 1J–L). FTY720 induced Ccl2mRNA levels (Fig. 1J),
whereas other family members, i.e. Ccl3 (Fig. 1K) and Ccl9 (Fig. 1L)
were downregulated. In contrast to FTY720, diethyl fumarate (fumar.)
did notmodulatemRNA abundance (Fig. 1A–L). This ﬁnding underscores
the speciﬁcity of the FTY720 dependent gene expression response.
In order to corroborate ﬁndings onmRNA level (Fig. 1) we analyzed
FTY720 mediated activity on neurons on protein level (Fig. 2). Here, we
employed primary cerebellar cultures (Fig. 2A, B) aswell as organotypic
cerebellar brain slices of P5 mice reﬂecting more closely in vivo condi-
tions (Fig. 2C-F). Samples were incubated with DMSO (as control),
FTY720 or BDNF as positive control (Fig. 2). Subsequently, cell lysates
were prepared and immunoblotting experiments with antibodies
directed against c-Fos, FosB, Egr1 and Egr2 were performed (Fig. 2A–
D). In agreement with the results obtained on mRNA level (Fig. 1), we
noted upregulation of c-Fos, FosB, Egr1 and Egr2 protein levels after
FTY720 application in both primary cerebellar neurons (Fig. 2A and
B) and cerebellar organotypic slices (Fig. 2C and D).
In cerebellar neurons, FTY720 upregulated c-Fos and Egr1 similarly
to effects observed for BDNF (Fig. 2A and B). FTY720 also upregulated
FosB and Egr2, a ﬁnding not observed for BDNF stimulation in cerebellar
neurons (Fig. 2A and B). In cerebellar slices, FTY720's potential to induceprotein abundance of these IEGs was comparable to (c-Fos, FosB, Egr1)
or exceeded (Egr2) BDNF's impact on protein expression of these
genes (Fig. 2C, D).
In addition, to immunoblotting (Fig. 2A–D),we performed immuno-
histochemical inspection of parafﬁn sections derived from these
organotypic cerebellar brain slices (Fig. 2E and F). Upon treatment
with DMSO (control; Fig. 2E) or FTY720 for 8 h (Fig. 2F), sections were
labeled for c-Fos expression along with NeuN to identify neurons. In
control treated cerebellar slices, no c-Fos expression was detectable
(Fig. 2E). In contrast, FTY720 administration resulted in c-Fos upregula-
tion in NeuN positive neurons (yellow neurons labeled with arrows in
Fig. 2F).
In summary, we describe a several gene classes encompassing
neuronal gene expression response elicited by FTY720.
3.2. FTY720 modulates neurite growth and growth cone morphology
Signaling by S1P, but so far not FTY720, was reported to modulate
axon growth and morphology of growth cones consisting of F-actin
rich ﬁnger-like ﬁlopodia (Fincher et al., 2014; Strochlic et al., 2008).
FTY720 induced genes encoding for components of the actin cytoskeleton
(Fig. 1). This tempted us to analyze whether FTY720 modulates neurite
growth and growth cone morphology (Fig. 3). Neurons were identiﬁed
by neuron-speciﬁc βIII tubulin expression and F-actin in growth cones
was visualized with phalloidin.
First of all, we determined the impact of FTY720 application on
cerebellar neurite growth (Fig. 3A–E). Notably, compared to control
cultures treated with DMSO (Fig. 3A), FTY720 administration for 24 h
(Fig. 3B) resulted in increased neurite growth. In a concentration
range between 10 and 50 nM FTY720 stimulated neurite growth in a
concentration-dependent manner, whereas higher concentrations
(100 nM) reduced neurite length (Fig. 3E). Of note, BDNF application
for 24 h also increased neurite growth (Fig. 3C and E), whereas
co-application of FTY720 with BDNF decreased neurite length (Fig. 3D
and E).
Similar to neurite growth, we observed that FTY720 administration
(Fig. 3B’) resulted in a concentration- and time-dependent increase of
growth cone area (Fig. 3F) and ﬁlopodia number (Fig. 3G) compared
to DMSO (Fig. 3A’). In fact, FTY720's activity on growth cones was com-
parable to BDNF (Meier et al., 2011). As seen for neurite growth, FTY720
and BDNF co-administration resulted in decreased growth cone area
and ﬁlopodia number (Fig. 3D′, F and G).
Taken together, FTY720 can increase neurite growth, growth cone
area and ﬁlopodia number in primary neurons.
3.3. FTY720 stimulates axon regeneration upon facial nerve injury
Upon nerve injury, the extent of axonal regeneration depends on the
potential of axotomized neurons to re-initiate axon growth and convert
growth-inert retraction bulbs into dynamic growth cones (Bradke et al.,
2012). Given FTY720's potential to stimulate neurite growth and
growth cone ﬁlopodia extension in primary neurons (Fig. 3), we exam-
ined whether FTY720 might likewise stimulate axon regeneration
in vivo (Fig. 4). For this, we employed the facial nerve lesion model in
mice (Moran and Graeber, 2004). The facial nerve connects motoneurons
residing in facial nuclei of the brainstem with facial muscles controlling
e.g. whisker and eyelid movements (see Fig. 4A). Axonal regeneration
was quantiﬁed by ﬂuorogold (FG) tracer injection into both whisker
pads 15 days after unilateral nerve transection. After three days of retro-
grade tracer transport, facial motoneurons (encircled in black in Fig. 4A)
incorporate the tracer, provided that nerve ﬁbers were re-connected
(red in Fig. 4A). For quantiﬁcation, the percentage of regenerated moto-
neurons was determined by calculating the ratio between FG numbers
on the lesioned and the unlesioned side. FTY720, or as control DMSO,
was administered by intraperitoneal injection every second day along
the entire experiment (n = 7 mice each group; see time-line in Fig. 4A).
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brain accumulation (Hait et al., 2014).
In control DMSO injected mice (Fig. 4D), approximately 30% of neu-
rons (quantiﬁed in Fig. 4V) regenerated after a total of 18days. In contrast,in FTY720 injectedmice, the number of FG positivemotoneurons (arrows
in Fig. 4E), indicative of successful axon regeneration,was almost doubled
(Fig. 4V). This was corroborated by more ATF3 positive motoneurons
present upon FTY720 treatment on the lesioned side (Supplementary
Fig. 3. FTY720 stimulates neurite growth and modiﬁes neuronal growth conemorphology. Cerebellar neurons were treated with indicated concentrations and times of FTY720 or BDNF.
Subsequently, neuronswere labeled for F-actin (red) andβIII tubulin (green). (A) Entire neuron (A) and growth cone (A′) of control neuron treatedwithDMSOonly. (A″ andA‴) represent
individual channels of F-actin (A″) and βIII tubulin (A‴) also shown in themerged picture in (A′). (B) FTY720 treatment increased the neurite length (B) and overall growth cone area and
number of F-actin positive ﬁlopodia (B′–B″). Individual ﬁlopodia aremarked by arrows in B′. (C) Similar to FTY720 (B), application of BDNF enhanced neurite growth (C) and growth cone
area as well as ﬁlopodia number (C′–C‴). (D) Co-administration of BDNF and FTY720 resulted in decreased neurite growth (D) and growth cone area and ﬁlopodia number (D′-D‴)
compared to individual treatment (B and C). (E) Quantiﬁcation of average neurite length after 24 h incubation with agents. (F and G) Quantiﬁcation of growth cone area (F) or
number of ﬁlopodia/growth cone (G) for the different conditions. In (E–G) represents every individual circle a single neuron (E) or growth cone (F and G) derived from one of at least
three independent experiments. Statistical signiﬁcance was calculated in relation to the DMSO treated control cultures. In conditions labeled with FTY in (E–G), “-“signiﬁes DMSO
treatment. The red lines indicate the mean values. Scale-bar (A–D; A′–D′) = 10 μm; (A″–D″; A‴–D‴) = 5 μm.
249S. Anastasiadou, B. Knöll / Experimental Neurology 279 (2016) 243–260Fig. 3). ATF3 is a regeneration associated gene (RAG) encoding for a
neuroprotective transcription factor (Hunt et al., 2012; Seijffers et al.,
2007). FTY720 also induced Atf3mRNA abundance in primary neurons
(Supplementary Fig. 3).
To monitor a potential neurodegenerative response, we quantiﬁed
numbers of motoneurons positive for SMI-32, a marker associated
with neurodegeneration (Laskawi and Wolff, 1996). On the unlesionedFig. 2. FTY720 upregulates IEG protein levels in cerebellar brain slices and primary cerebellar
indicated. FTY720 treatment upregulated protein abundance of c‐Fos and Egr1 similar to BD
(B) Quantiﬁcation of protein levels in relation to GAPDH. (C) P5 organotypic cerebellar brain c
Subsequently, protein lysates were subjected to immunoblotting experiments using antibodie
Fos, FosB, Egr1 and Egr2 at all time-points investigated. BDNF application also resulted in an
GAPDH relative to DMSO control set to 1. (E and F) Parafﬁn sections of organotypic cerebellar
and anti-NeuN (green) directed antibodies along with DAPI (blue) to stain cell nuclei. After
F) were detectable in comparison to control DMSO treated slices (E). Scale-bar (E, F) = 100 μmside, the number of SMI-32 positive neurons was expectedly low
(Fig. 4F and G). In opposite to this, on the lesioned side, we noted
more SMI-32 positive neurons (Fig. 4H and I). We also observed a
consistent but statistically not signiﬁcant SMI-32 reduction in the
FTY720 treated animal group (Fig. 4I), compared to the DMSO group
(Fig. 4H; quantiﬁed in Fig. 4W). This indicates reduced motoneuron
degeneration upon injury by FTY720.cultures. (A) Cerebellar cultures were stimulated with FTY720 or BDNF for time-points
NF, whereas FTY720, but not BDNF, resulted in enhanced FosB and Egr2 protein levels.
ultures were stimulated with FTY720, DMSO (control) or BDNF for time-points indicated.
s indicated. Stimulation with FTY720 resulted in elevated protein levels of all four IEGs, c‐
increase of IEG protein abundance. (D) Quantiﬁcation of protein levels normalized to
brain slices, incubated with DMSO (E) or FTY720 (F) were labeled with anti-c‐Fos (red)
8 h of FTY720 treatment (F), individual c‐Fos positive neurons (yellow, see arrows in
.
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analyzed whether FTY720 altered microglia (Fig. 4J–M) and astrocyte
(Fig. 4N–Q) activation in the deafferented facial nuclei (quantiﬁed
in Fig. 4X and Y). We noted a strong increase in the number of IBA-positive microglia (Fig. 4L and M) and GFAP-positive astrocytes (Fig. 4P
and Q) on the injured side compared to unlesioned facial nuclei (Fig. 4J,
K, N and O). However, this immune cell activation was comparable in
DMSO and FTY720 treated animals (compare Fig. 4L and M and Fig. 4P
251S. Anastasiadou, B. Knöll / Experimental Neurology 279 (2016) 243–260and Q), suggesting that FTY720 does not obviously impinge on axonal
regeneration through modulation of brain resident immune response.
An obvious cause affecting axonal regenerationwould be differential
motoneuron loss between experimental groups upon injury. For this,
we determined the number of Nissl positive motoneurons on the
lesioned side in relation to the unlesioned side (set to 100%). This
quantiﬁcation revealed a motoneuron loss of approximately 10% on
the lesioned compared to the intact facial nucleus in both DMSO
and FTY720 treated animals (Fig. 4R–U and Z).
FTY720 might enhance axonal regeneration through direct stimula-
tion of neurite growth, as demonstrated for primary cerebellar neurons
before (Fig. 3). As facial nerve lesion is amodel system of PNS injury, we
analyzed whether FTY720 might also enhance neurite growth of PNS
neurons (Fig. 5). For this, we cultured adult mouse DRG neurons in
the presence of FTY720. As a positive control, we applied nerve growth
factor (NGF), an established stimulator of DRG neurite growth (Fig. 5B).
Similar to CNS neurons (Fig. 3), FTY720 administration resulted in
increasedDRGneurite growth (Fig. 5C; quantiﬁed in E–G). Interestingly,
co-application of NGF and FTY720 further enhanced neurite growth
compared to individual application (Fig. 5D).
In summary, individual FTY720 incubation or a combined treatment
of DRG neurons with NGF and FTY720 stimulated PNS neuron growth.
FTY720 modulates the extent of myelination in rodent MS models
(Blanc et al., 2014; Choi et al., 2011; Kim et al., 2011; Papadopoulos
et al., 2010). In order to analyze whether FTY720 modulates myelination
processes after PNS nerve injury, we inspected the facial nerve for
Schwann cells and myelin content (Fig. 6).
At 18 days post injury, signals of S100β positive Schwann cells were
comparable between intact and injured nerve of control treated animals
(Fig. 6A and C). In contrast, we observed an increased number of
Schwann cell signals upon FTY720 treatment in the intact nerve
(Fig. 6B) and even more Schwann cells in the lesioned nerve (Fig. 6D;
quantiﬁed in Fig. 6I). Inspection of myelin levels with anti-MBP (myelin
basic protein) directed antibodies revealed comparable myelin content
in unlesioned nerves of control and FTY720 treatedmice (Fig. 6E and F).
Upon nerve injury, MBP signals were reduced in lesioned nerves of
control treated animals (Fig. 6G). In contrast, in injured facial nerves
of FTY720 treated animals, MBP levels were increased compared to
control animals (Fig. 6H; quantiﬁed in J).
In summary, we here describe a ﬁrst stimulatory FTY720 function in
peripheral axon regeneration.
3.4. FTY720's impact on neurogenesis in the hippocampus and subventricular
zone (SVZ)
Sphingosine signaling was previously connected to neurogenesis
(McGiffert et al., 2002; Mizugishi et al., 2005). Thus, we were interested
to analyzewhether FTY720 administration overmore than 2weeks (see
Fig. 4A) might affect adult neurogenesis. For this, we performed
immunehistological staining (Fig. 7) with the type 1 stem cell marker
nestin and doublecortin (DCX), a marker for immature neurons
(Kempermann et al., 2004). We analyzed two neurogenic regions, theFig. 4. FTY720 stimulates peripheral axon regeneration in vivo. (A) Experimental outline of the
lines. The position of facial motoneurons in the nucleus facialis is labeled by a black dotted line. T
injected 15 days after axotomy and animals were analyzed three days thereafter. (B–E) The nuc
treatment enhanced the number of FG positive motoneurons on the lesioned side (E) compare
arrows in D and E. (F–I) The number of motoneurons positive for the neurodegeneration mark
side (F and G). FTY720 injection (I) slightly reduced the number of SMI-32 positive neurons com
GFAP-positive astrocytes (N-Q)were comparably induced by facial nerve lesion inDMSO (L and
O). (R–U) Total numbers of facial motoneurons were labeledwith Nissl. Numbers ofmotoneuro
(V) Quantiﬁcation of axon regeneration. The number of regeneration-indicating tracer positiv
lesioned side were normalized to the numbers on the unlesioned side (set to 100%). (W) Qua
was decreased by approximately 20% upon FTY720 treatment, however, this result was stat
P = 0.21). SMI-32 positive motoneurons on the unlesioned side were set to 100%. (X and Y)
animals on the lesioned side. Numbers on the unlesioned side were set to 100%. (Z) Nissl po
FTY720 treated animals. Each circle or square represents one animal analyzed. The dashed lin
are expressed as mean ± SD. Scale-bar (B–U) = 100 μm.dentate gyrus (DG) of the hippocampus and the subventricular zone
(SVZ; Kempermann et al., 2004).
In the DG, we observed a subtle but statistically not signiﬁcant
increase in DCX (Fig. 7B and F) and Nestin (Fig. 7D and H) positive
cells upon FTY720 treatment compared to DMSO injected animals
(Fig. 7A, E, C and G). In the SVZ, we observed DCX (Fig. 7I and M) and
nestin (Fig. 7K and O) positive cells along the margins of the ventricle
in DMSO treatedmice. As seen for the hippocampus, FTY720 had overall
a positive effect on neurogenesis in the SVZ. Now, the number of DCX
positive neurons was signiﬁcantly increased by FTY720 (Fig. 7J and N;
quantiﬁed in S) and numbers of nestin positive cells were also slightly
elevated (Fig. 7L and P; quantiﬁed in T).
Thus, our ﬁnding is congruent with recent data described for the DG
(Efstathopoulos et al., 2015), indicating a positive role of FTY720 in
neurogenesis.
3.5. FTY720 signaling is modulated by neuronal sphingosine receptors
To decipher which S1P receptors might be engaged by FTY720 on
neurons, mRNA abundance of all ﬁve S1P receptors was quantiﬁed in
primary cerebellar neurons (Fig. 8A). We observed highest expression
of S1pr3 and somewhat lower of S1pr1 and S1pr2, whereas S1pr4 and
S1pr5where almost absent from these primary neurons (Fig. 8A).
It is known from the literature that FTY720 binds preferentially to
S1PR1, S1PR3 and S1PR5 out of the ﬁve S1P receptors (Brunkhorst
et al., 2014). In contrast, S1PR2 is not recognized by FTY720
(Brunkhorst et al., 2014). In order to decipher S1P receptors engaged
by FTY720 we employed S1P receptor antagonists (Fig. 8B–J; see
Fig. 11). This included the S1PR1 antagonist NIBR-0213, the S1PR2
antagonist JTE-013 and the S1PR3 antagonist TY52156 (Huwiler and
Pfeilschifter, 2006; Murakami et al., 2010; Quancard et al., 2012).
As before (Fig. 1), FTY720 application alone for 24 h resulted in
robust induction of all genes analyzed (Fig. 8B–J). Interestingly,
co-application of FTY720 and the S1PR2 antagonist JTE-013 enhanced
even further gene expression compared to FTY720 alone. This was
observed for eight out of nine genes analyzed (Fig. 8B and D–J), the
exception being FosB (Fig. 8C). This suggests that S1PR2 signaling inhibi-
tionpotentiates FTY720's potential to induce neuronal gene expression. In
contrast, NIBR-0213 co-administration resulted in a modest inhibition of
several FTY720 induced genes including Egr1 (Fig. 8D), Egr2 (Fig. 8E),
Acta (Fig. 8F), Cnn1 (Fig. 8G), Tagln (Fig. 8H) and Bdnf (Fig. 8I) suggesting
that FTY720 requires at least to some extent S1PR1 signaling. Interference
with S1PR3 signaling by TY52156 administration had an opposite effect
on FTY720 mediated IEG and cytoskeletal gene expression. Here,
FTY720's potential to induce IEGs such as c-Fos (Fig. 8B) and FosB
(Fig. 8C) was signiﬁcantly further enhanced, as also seen for Egr1 and
Egr2 (Fig. 8D and E). In opposite to this, FTY720mediatedmRNA induc-
tion of all three actin cytoskeletal (Fig. 8F–H) was signiﬁcantly reduced
by inhibition of S1PR3 receptors.
In contrast to FTY720, S1P did not generally induce gene expression
with one exception, Ccl2. Here, S1P application resulted in strong Ccl2
mRNA induction (Fig. 8J). Of note, this Ccl2 induction appears completelyfacial nerve lesion model. The facial nerve is represented by solid blue, dashed blue or red
ime-line indicates FTY720 or DMSO injection every second day. Fluorogold (FG) tracer was
leus facialiswas stained with anti-FG directed antibodies to visualize the FG tracer. FTY720
d to DMSO injected animals (D). Individual FG tracer positive motoneurons are marked by
er SMI-32 was upregulated upon facial nerve lesion (H and I) compared to the unlesioned
pared to control (H; see quantiﬁcation inW). J–Q) IBA-positive microglial cells (J–M) and
P) and FTY720 (MandQ) treated animals compared to the unlesioned side (J and N; K and
nswere slightly decreased upon lesion in both DMSO (T) and FTY720 (U) injected animals.
e motoneurons was almost doubled upon FTY720 treatment. FG-positive neurons on the
ntiﬁcation of SMI-32. The number of SMI-32 positive motoneurons on the lesioned side
istically not signiﬁcant (DMSO: 213 ± 19 neurons; FTY720: 177 ± 18 neurons; N = 7;
Microglia (X) and astrocytes (Y) were comparably induced in DMSO or FTY720 treated
sitive motoneurons were reduced by approximately 10% upon lesion in both DMSO and
e in (N–R) represents values obtained at the unlesioned side that were set to 100%. Data
Fig. 5. FTY720 stimulates DRG neurite growth. (A–D) Adult mouse DRG neurons were incubated with NGF (B), FTY720 (C) or both together (D) and subsequently stained for neuron-
speciﬁc βIII tubulin (green) and F-actin (red). NGF (B) and FTY720 (C) treatment alone stimulated DRG neurite growth. Combined treatment of NGF and FTY720 (D) even further
enhanced neurite growth compared to control (A) and individual treatments of NGF or FTY720. (E–F) Quantiﬁcation of DRG neurite growth by calculating average neurite length (E),
the percentage of neurons with longest neurites (F) and number of neurons with neurite growth normalized to the area (G). Each circle in (E) represents one neuron. The red lines in
(E) indicate the mean values. Statistical signiﬁcance was calculated in relation to the DMSO treated control cultures (FTY “-“and NGF “-“). Scale-bar (A–D) = 50 μm.
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abrogated Ccl2 induction by S1P (Fig. 8J). This is in contrast to S1PR2's
inhibitory impact on FTY720 signaling (see above).
Wenext analyzedwhether S1PR inhibitorsmight also affect cerebellar
neurite growth (Fig. 8K and L). Here, individual inhibition of S1PR1 and
S1PR2 enhanced average neurite length (Fig. 8K) and the percentage of
neurons bearing longest neurites (N40 μm; Fig. 8L). Inhibition of S1PR3
alone also enhanced neurite growth, however not signiﬁcantly. Upon
co-administration of FTY720 with S1PR inhibitors, only interference
with S1PR1 resulted in decreased neurite growth (Fig. 8K and L). This
suggests that FTY720 requires to some extent S1PR1 for signaling.
In summary, FTY720 stimulated neuronal gene expression and
neurite growth is modulated by S1P receptor activity.
3.6. FTY720 recruits G12/13 G protein-RhoA-MRTF-A/SRF signaling in
neurons
FTY720 recognizes S1P receptors, including those connected with
G12/13 and RhoA signaling (Brinkmann et al., 2010; Brunkhorst et al.,
2014). Activated RhoA-GTPase enhances nuclear activity of the
transcription factor SRF and its cofactor MRTF-A. In order to analyze
whether FTY720 triggers a neuronal signaling cascade through G12/
13-RhoA-MRTF-A/SRF engagement, we employed speciﬁc blocking
strategies for each of the signaling intermediates (Fig. 9). Overexpres-
sion of the RGS (regulator of G protein signaling) domain of the
Rho-GTPase guanine nucleotide exchange factor (Rho-GEF) Lsc
(Lsc-RGS) interferes with Gα12/13 signaling (Moepps et al., 2008).
RhoA function was blocked by the C3 transferase (Barth et al.,
1998) and MRTF-A was inhibited through overexpression of a dominant
negative MRTF-A protein (Miralles et al., 2003). For a summary of
blocking strategies see Fig. 11.
Inspection of the three IEG genes, c-Fos (Fig. 9A), Egr1 (Fig. 9B) and
Egr2 (Fig. 9C) revealed induction of all three IEGs by FTY720 as before(Figs. 1 and 8). Inhibition of individual components of the G12/13-
RhoA-MRTF-A pathway did not abrogate mRNA induction of all three
IEGs (Fig. 9A–C). In fact, mRNA abundance of c-Fos or Egr2 upon
blocking individual components of the G12/13-RhoA-MRTF-A signaling
pathway was actually augmented upon FTY720 administration (Fig. 9A
and C).
In contrast, FTY720 required for induction of all three “actin genes”,
i.e. Acta, Cnn and Tagln an intact G12/13-RhoA-MRTF-A signaling
pathway (Fig. 9D–F). For instance, FTY720 mediated upregulation of
Acta was abrogated by inhibition of G12/13 G proteins, the RhoA-
GTPase or MRTF-A gene transcription (Fig. 9D). The same holds true
for Tagln (Fig. 9F) and to a weaker extent for Cnn (Fig. 9E). Data in
Fig. 9D–F suggest that RhoA is involved in FTY720 signaling. We
analyzed this further by inspecting whether downstream of RhoA, the
known RhoA effector molecule coﬁlin (Bamburg et al., 2010), is
involved in FTY720 signaling. For this, primary cerebellar neurons
were stimulatedwith FTY720 for 1 h and protein lysateswere subjected
to immunoblotting with antibodies recognizing total coﬁlin and phos-
phorylated coﬁlin levels (Supplementary Fig. 4). Serine 3 phosphorylat-
ed coﬁlin represents the inactive form of this actin severing protein
(Bamburg et al., 2010). Total coﬁlin protein abundance was not affected
by FTY720 administration (Supplementary Fig. 4). In contrast, therewas
a subtle, but statistically not signiﬁcant increase, in phosphorylated
coﬁlin abundance by FTY720 application (Supplementary Fig. 4). This
suggests a modest impact of FTY720 on coﬁlin activity.
Next, we asked whether neuronal signaling elicited by FTY720
targets SRF mediated gene transcription. For this, we performed qPCR
experiments in primary cerebellar neurons focusing on the 24 h time
point of FTY720 application (Fig. 10). In order to evaluate a potential
SRF dependence of FTY720 action, we included siRNA mediated SRF
downregulation. In addition, we analyzed siRNA mediated CREB
downregulation, a transcription factor previously reported to be
activated by FTY720 (Deogracias et al., 2012). Total SRF, total CREB
Fig. 6. FTY720 enhances Schwann cell signals and myelin content in lesioned nerves. Unlesioned and lesioned facial nerves of control or FTY720 treated mice were labeled for Schwann
cells with S100β (A–D) or myelin with MBP (E-H) 18 days after injury. (A–D) Schwann cell signals were elevated in both unlesioned (B) and lesioned (D) facial nerves of FTY720 treated
animals compared to control treated animals (A and C). (E–H) Upon injury, myelin content measured by MBP was elevated in FTY720 (H) compared to control treated animals (G). (I,
J) Quantiﬁcation of S100β (I) and MBP (J) signals per area. Each circle, triangle or square represents one animal analyzed. Data are represented as mean± SD. Scale-bar (A-H) = 100 μm.
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respective Srf or Creb directed siRNA compared to a control siRNA
(siCtr.; Fig. 10A).
In the presence of control siRNA, FTY720 induced cFos (Fig. 10B) and
FosB (Fig. 10C) mRNA levels as before in non-electroporated neuronal
cultures (Figs. 1 and 8). Upon siRNA mediated downregulation of SRF
and CREB, FTY720 still induced cFos (Fig. 10B) and FosB (Fig. 10C) sug-
gesting that this gene response is neither SRF nor CREB dependent. In
contrast, FTY720 required the presence of SRF but not CREB for full in-
duction of the IEGs Egr1 (Fig. 10D) and Egr2 (Fig. 10E).
Out of the four actin cytoskeletal genes tested, three, i.e. Acta
(Fig. 10F), Cnn (Fig. 10H) and Tagln (Fig. 10I) but not Tpm1a (Fig. 10G)
required SRF but not CREB for upregulation by FTY720. Finally, Bdnf
(Fig. 10J) was upregulated by FTY720, however neither in an SRF- nor
CREB-dependent manner. Expression of Ccl2, Ccl3, Ccl9 chemokines
and S1pr1‐5 receptors was not affected by siRNA mediated SRF deple-
tion suggesting that expression of those genes is not SRF dependent
(data not shown).
Taken together, FTY720 engages a G12/13-RhoA-MRTF-A/SRF
signaling pathway in neurons to regulate actin cytoskeletal genes but
not IEGs.
We also tested whether FTY720's impact on growth cone area and
ﬁlopodia number requires SRF (Fig. 10K–P). In cerebellar neurons
expressing control siRNAs (Fig. 8K and L), FTY720 elevated growth
cone area and ﬁlopodia number as before (Fig. 3). In contrast, upon
SRF depletion, FTY720 did not enhance growth cone area andﬁlopodia number (Fig. 10M and N). This indicates an SRF dependence
of FTY720 to modulate growth cone morphology (Fig. 10) and also
neurite growth (data not shown).
4. Discussion
4.1. Neuronal functions of FTY720
In this study, we report direct modulation of neuronal function by
FTY720. We observed two neuronal FTY720 activities, i.e. induction of a
gene expression response (e.g. Figs. 1 and 8) and modulation of neuronal
morphology, neurite growth and axonal regeneration (Figs. 3–5).
FTY720 increased mRNA abundance of several genes including IEGs
(c-Fos, FosB, Egr1, Egr2, Bdnf), cytoskeletal genes and Ccl2.We identiﬁed
with SRF a ﬁrst transcription factor mediating such FTY720 gene induc-
tion in neurons (Fig. 10 and see below). Thus, similar to BDNF signaling
(Chang et al., 2004; Kalita et al., 2006; Meier et al., 2011), SRF is also
involved in FTY720 signaling. In addition to gene induction, FTY720
appears also to repress neuronal gene expression of e.g. Ccl3 and Ccl9
(Fig. 1), in line with a recent report in Schwann cells (Heinen et al.,
2015).
What might be the functional consequences of such FTY720
upregulated gene products for neurons?
CCL chemokinesmediate a brain intrinsic immune response involving
astrocytes and microglia (Reaux-Le Goazigo et al., 2013). For instance,
during PNS nerve injury CCL2 modulates Wallerian degeneration and
Fig. 7. FTY720's impact on hippocampal and SVZ neurogenesis. (A–H) The dentate gyrus (DG) of the hippocampuswas stained for NeuN and doublecortin (DCX; A, B and E, F) or nestin (C,
D and G, H) expression. DCXwas found in the subgranular zone of the DG in both DMSO (A and E) and FTY720 (B and F) treated animals. Nestin positive cell bodies and protrusionswere
found in theDGofDMSO (C andG) and FTY720 (D andH) treatedmice. (E–H) are highermagniﬁcations of boxed areas in (A–D). (I–P) In the SVZ of controlmice, DCX (I andM) andnestin
(K and O) positive cells were found along the borders of the ventricle. FTY720 enhanced the number of DCX positive immature neurons (J and N; see S) and also slightly the number of
nestin positive neurons (L and P; see T). (M–P) are highermagniﬁcations of boxed areas in (I–L). (Q–T) Quantiﬁcation of DCX (Q and S) or nestin (R and T) positive cells in the DG (Q and
R) or SVZ (S and T). Overall, FTY720 enhanced signals for both neurogenesis markers in both regions, however statistically signiﬁcantly only for DCX in the SVZ (S). Each circle or square
represents one animal analyzed. Data are expressed as mean ± SD. Scale-bar (A–D; I–L) = 50 μm; (E–H; M–P) = 50 μm.
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et al., 2005). Thus, through upregulation of CCL chemokines, FTY720
might inﬂuence Wallerian degeneration and myelin function during
PNS axon regeneration (see also below).
FTY720 also induced several IEGs including c-Fos, FosB, Egr1, Egr2
and Bdnf (Fig. 1). Interestingly, three genome-wide expression studies
identiﬁed overrepresentation of IEGs such as c-Fos and Egr1 in human
MS patient tissue, suggesting important roles of these IEGs in MS path-
ogenesis (Kotelnikova et al., 2015; Liu et al., 2013; Riveros et al., 2010).Many of these IEGs encode for neuronal activity-induced and neuronal
plasticity-associated transcription factors that are rapidly induced by
neuronal activation. For instance, c-Fos induction is a bona ﬁdemarker
to identify synaptically activated neurons. In turn, such IEGs elicit a
second (delayed) gene transcription response modulating synaptic
plasticity related properties of neuronal networks related to learning
and memory (Perez-Cadahia et al., 2011). Thus, through governing a
neuronal IEG response, FTY720 might directly regulate plasticity-related
properties of neuronal circuits also in human MS patients (see summary
255S. Anastasiadou, B. Knöll / Experimental Neurology 279 (2016) 243–260Fig. 11). Such beneﬁcial FTY720 effects on learning and memory were
recently reported in mice (Hait et al., 2014). In addition to modulation
of synapse function, c-Fos and Egr transcription factors stimulate neurite
growth in vitro (Levkovitz and Baraban, 2002; Levkovitz et al., 2001),
axon sprouting in vivo (Watanabe et al., 1996) and are induced in some
PNS lesion models (Herdegen et al., 1993; Herdegen and Leah, 1998).
Thus, although we do not provide functional evidence in this study, it is
reasonable to argue that FTY720 mediated upregulation of IEGs such as
c-Fos, Egr1 or Egr2might also modulate neurite growth in vitro and axon
regeneration in vivo.
In addition to IEGs, FTY720 induced mRNA levels of genes encoding
for components of the actin cytoskeleton such as Acta, calponin (Cnn),
transgelin (Tagln) and tropomyosin (Tpm1a) family ABPs (Fig. 1). The
actin cytoskeleton is an important regulator of neuronal growth cone
dynamics and is also involved in stimulation of axon growth and regen-
eration (Bradke et al., 2012). In this study we observed that FTY720 up-
regulated several actin isoforms (Fig. 1). Interestingly, during several
PNS injuries, including facial nerve axotomy (Tetzlaff and Bisby, 1990;
Tetzlaff et al., 1988), an early but transient upregulation of actin levels
was reported. Thus, FTY720 treatment might enhance abundance of
actin isoforms during an early phase of axonal regeneration. In addition
to actin isoforms, we observed induction of the ABPs calponin and
tropomyosin by FTY720 (Fig. 1). These ABPs stabilize ﬁlopodial F-actin
(Danninger and Gimona, 2000), enhance cell motility (Wu et al.,
2014) and regulate neuritogenesis and growth cone shape
(Curthoys et al., 2014; Pape et al., 2008; Schevzov et al., 2005).
Thus, through induction of such speciﬁc ABPs FTY720 might exert a
direct function on neuronal actin dynamics and thereby on growth
cone shape and neurite growth.
In contrast to the actin cytoskeleton, we have not observed obvious
effects of FTY720 on overall tubulin, tyrosinated or acetylated tubulin
abundance (data not shown). FTY720's potential to inﬂuence the actin
or ABP gene expression suggests modulation of actin-dependent
processes such as neuronal morphology and motility. Indeed, FTY720
increased growth cone area and number of F-actin rich ﬁlopodia as
well as neurite growth in vitro (Figs. 3 and 5) and axonal regeneration
in vivo (Fig. 4). Thus, FTY720 appears to have positive effects on neuro-
nal morphology and nerve ﬁber growth relying on actin cytoskeletal
dynamics.
In contrast to FTY720, S1P was reported to induce growth cone
collapse (Fincher et al., 2014; Strochlic et al., 2008) suggesting that
FTY720 and S1P have opposite effects on neuronal morphology. Of
note, FTY720 had a concentration-dependent effect on neurite growth
with low and high concentrations stimulating or inhibiting neurite
growth, respectively (Fig. 3E). Thus, similar to other treatments, e.g.
ephrins (Hansen et al., 2004) and taxol employed in spinal cord injuries
(Hellal et al., 2011), there might be a speciﬁc FTY720 concentration
range beneﬁcial for stimulating neuronal motility. We also noted,
perhaps surprisingly, reduced growth cone shape and neurite growth
upon co-application of FTY720 with BDNF, in contrast to individual
application of either molecule in CNS neurons (Fig. 3). Currently, the
implication of this counteraction remains unresolved, however a differ-
ent neurotrophin, NT-3, was also reported to interfere with FTY720's
impact on cells (Coelho et al., 2007). It is worth noting that in contrast
to CNS neurons, co-application of FTY720with a different neurotrophin,
NGF, enhanced neurite growth in PNS neurons compared to individual
application (Fig. 5).
Herein, we present ﬁrst data demonstrating stimulation of axonal
regeneration in the peripheral nervous system by FTY720 injection in
mice (Fig. 4). In CNS spinal cord injury, FTY720 enhances functional
recovery most likely through interfering with neuroinﬂammation (Lee
et al., 2009). In this study, FTY720's beneﬁcial impact on PNS axon
regenerationmost likely does not involve neuroinﬂammation, as judged
by comparable microglia and astrocyte inﬁltration in the lesion side
(Fig. 4). Our data favor direct stimulation of severed nerve ﬁber growth
by FTY720 also in vivo (see summary Fig. 11). Indeed, FTY720 enhancedgrowth cone morphology and neurite growth of CNS neurons in vitro
(Fig. 3). Besides CNS neurons, FTY720 alone or together with NGF also
enhanced neurite growth of PNS neurons (Fig. 5). Interestingly, NGF,
an established stimulator of PNS neurite growth, is strongly upregulated
by facial nerve injury (Stern et al., 2012). Thus, such NGF upregulation
upon facial nerve injury together with the injection of FTY720 might
result in a concerted action of both molecules facilitating nerve growth
and therebyPNSaxonal regeneration. In linewith such apro-regenerative
FTY720 function we observed FTY720 mediated induction of the neuro-
protective RAG ATF3, also known to stimulate axon growth and regener-
ation (Supplementary Fig. 3; Seijffers et al., 2006, 2007).
In addition to axon growth, we observed that FTY720 enhanced
Schwann cell numbers and abundance of MBP positive myelin in the
injured facial nerve compared to control treated animals (Fig. 6). This
is in line with previous reports showing FTY720's potential to stimulate
a pro-regenerative Schwann cell phenotype (Heinen et al., 2015) and
augment MBP expression during remyelination (Jackson et al., 2011).
This suggests that FTY720 might enhance facial nerve regeneration
also through modulation of Schwann cell function.
4.2. How might FTY720 modulate neuronal signaling?
FTY720 can modulate signaling, e.g. epigenetic modiﬁcations,
through a direct nuclear localization (Hait et al., 2014). In addition,
FTY720 acts at the cell surface as a S1P receptor agonist or, upon
prolonged treatment, as antagonist through S1PR internalization
(Chun and Brinkmann, 2011). Our data suggest that FTY720 mediates
a signaling cascademodulated by S1P receptors. First of all, we observed
neuronal expression of S1P receptors known to be engaged by FTY720
(i.e. S1PR1 and S1PR3 as also reported by others; Deogracias et al.,
2012; Kays et al., 2012). Pharmacological interference with S1PR1
receptors revealed a subtle dependence of FTY720 signaling on this
receptor for gene expression and neurite growth (Fig. 8). Strikingly
however, S1PR2 inhibition with the antagonist JTE-013, augmented
FTY720's individual activity on gene expression in primary neurons
(Fig. 8). This suggests that S1PR2 receptor signaling, a receptor actually
not recognized by FTY720 (Chun and Brinkmann, 2011), counteracts
FTY720 activity by so far unknown mechanisms. Notably, such co-
application of FTY720 along with JTE-013 might be exploited to further
enhance FTY720's individual activity, a ﬁnding with potential therapeutic
relevance. In fact, JTE-013 was recently shown to enhance the neurite
growth and regeneration potential of primary neurons (Kempf et al.,
2014).
Finally, we show that inhibition of S1PR3 signaling had a dual effect
on FTY720 mediated gene expression. S1PR3 receptor seems to inhibit
FTY720's potential to induce IEGs, whereas this receptor was required
by FTY720 for full induction of cytoskeletal genes (Fig. 8).
Downstream of S1P receptors, we demonstrate that FTY720
signaling targets the transcription factor SRF. Indeed, siRNA mediated
SRF knockdown revealed that most of the genes induced by FTY720
required SRF except for c-Fos and FosB (Fig. 10). We further deciphered
potential signaling intermediates between FTY720 and SRF and identi-
ﬁed G12/13, RhoA and MRTF-A as potential candidates (Fig. 9 and
summary Fig. 11). Both, G12/13 and RhoA are known MRTF-A/SRF
activators (Mao et al., 1998; Olson and Nordheim, 2010). Of note, this
G12/13-RhoA-MRTF-A/SRF signaling cascade was mainly involved in
mediating FTY720's activity on cytoskeletal but not IEG gene expression
and (Fig. 9 and summary Fig. 11), a ﬁnding congruent with previous
data in neuronal and non-neuronal cells (Olson and Nordheim, 2010).
With regard to IEG induction, our data suggest that FTY720 also requires
SRF, however, this time SRF might cooperate with different cofactors,
e.g.members of the TCF family (Knoll and Nordheim, 2009).
In summary, SRF is an important regulator of neuronal actin dynamics
(Knoll and Nordheim, 2009; Olson and Nordheim, 2010) and stimulates
axon growth and regeneration in vivo (Knoll et al., 2006; Lu and
Ramanan, 2011; Stern et al., 2013; Wickramasinghe et al., 2008). Thus,
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Fig. 9. FTY720 modulates gene expression through a G12/13-RhoA-MRTF-A cascade. (A–F) Cerebellar neurons were stimulated with FTY720 in the presence or absence of selective
pathway inhibitors. Overexpression of Lsc-RGS or dominant-negative (dn) MRTF-A inhibits G12/13 and the SRF cofactor MRTF-A, respectively. Bath application of the C3 toxin
speciﬁcally interferes with RhoA-GTPase activity. Subsequently, qPCR experiments were performed, depicting relative mRNA levels of cFos (A), Egr1 (B) or Egr2 (C) upon the various
treatments indicated. (A–C) In the absence of pathway blocking agents, FTY720 robustly augmented mRNA levels of all three IEGs. In comparison to FTY720 alone, blocking G12/13
and RhoA signaling further elevated mRNA abundance of cFos (A) and Egr2 (C) but not Egr1 (B). In contrast, blocking MRTF-A did not modulate FTY720's induction of all three IEGs.
(D–F) Blocking of all three signaling intermediates, G12/13, RhoA and MRTF-A, prevented induction of all three actin cytoskeletal genes, Acta (D), Cnn (E) and Tagln (F) by FTY720.
Numbers in bars in (A) indicate the number of independent cell cultures analyzed for each gene depicted. Data are expressed as mean ± SD.
257S. Anastasiadou, B. Knöll / Experimental Neurology 279 (2016) 243–260through connecting with SRF, FTY720 might have direct access to actin
cytoskeleton based processes such as modulation of growth cone shape
and axon growth and re-growth after injury.
4.3. Implications for treatment of MS and other neurological diseases
Enhancing neuroprotection is a goal shared by many therapeutic
efforts to cure neurodegenerative diseases. In recent years, several mole-
cules have been attributed neuroprotective effects in animal models
of neurodegenerative diseases. For instance, melanocortins prevent
cognitive decline in mouse models of Alzheimer's disease (Giuliani et al.,
2011, 2014, 2015). Melancortins might exert their neuroprotective activ-
ity through enhancing neurogenesis (Giuliani et al., 2011, 2014, 2015), a
function also reported for FTY720 (Fig. 7 and Efstathopoulos et al., 2015).
In this study, we identiﬁed FTY720 as a potential candidate providing
neuroprotection in neurological diseases including – but not limited to –
MS. In latest MS research, the neuronal compartment has been assigned
an important role at early stages of MS pathology. Now, axonal damage
and neurodegeneration are viewed as a prime MS cause (Luessi et al.,
2012; Trapp and Nave, 2008). Thus, stressing the importance of neurode-
generation inMS in addition to inﬂammation has signiﬁcant implications
for treatment strategies. In this regard, it might be particularly importantFig. 8. FTY720 mediated gene expression is modulated by S1P receptor antagonists. (A) Prima
subsequently cDNA was subjected to qPCR analysis with S1P receptor primer pairs as indicated.
weaker expressed and S1pr4 and S1pr5were not expressed at all. Treatment with FTY720 or BD
were stimulated for 24 h with FTY720 or S1P in the presence or absence of speciﬁc S1PR1 (NIBR
indicated were determined. FTY720 treatment alone stimulated mRNA abundance of all genes a
induction in almost all genes analyzed, except for FosB (C). NIBR co-application, in contrast, re
Interference with S1PR3 signaling further enhanced FTY720's potential to induce IEGs (B-E), w
expression only of one single gene, namely induction of Ccl2 (J). Co-application of S1P with JTE-0
on FTY720 (see above). (K and L) Quantiﬁcation of average cerebellar neurite length (K) or per
(K) represents one neuron. The red lines in (K) indicate the mean values. Numbers in (B) indi
FTY720 treatment alone, if not indicated otherwise. Data are expressed as mean ± SD.to stimulate neuroprotective and neuroregenerative processes of
damaged neurons in MS therapy. In this study, we showed such
FTY720 mediated neuroprotective and neurorestorative functions
directly on CNS neurons. FTY720's potential to elicit neuronal activity
associated gene expression as well as modulation of actin dependent
growth cone shape, neurite growth and axonal regeneration might
enhance neuroprotective processes in MS affected CNS neurons and
dampen MS associated neuronal impairments including synaptopathies,
axonal damage and neuronal demise.
In addition, our data suggest that FTY720 treatment might also be
beneﬁcial for treatment of other neurological diseases including central
and peripheral nerve injuries requiring improvement of neuroprotec-
tive or neuroregenerative processes.
5. Conclusions
FTY720 (FTY720) is now a routinely employed drug to treat multiple
sclerosis. So far, FTY720's mode of action was believed to mainly involve
sequestration of auto-reactive immune cells in lymph nodes. In this
study, we demonstrate that FTY720 has direct actions on neurons includ-
ing stimulation of a neuronal-plasticity associated gene expression
response, nerve ﬁber growth and axonal regeneration of lesioned nervesry cerebellar neurons were incubated with FTY720 or BDNF for timepoints indicated and
Out of the ﬁve S1P receptors, S1pr3mRNA abundance was strongest, S1pr1 and S1pr2were
NF did not obviously affect mRNA abundance of S1pr1‐5. (B–J) Primary cerebellar neurons
), S1PR2 (JTE-013) and S1PR3 (TY-52156) antagonists. Subsequently, mRNA levels of genes
nalyzed. Co-application of FTY720 with JTE-013 resulted in further augmentation of mRNA
sulted in a slight inhibition of FTY720 mediated gene induction (see e.g. D, F, G, H and I).
hereas cytoskeletal gene expression was reduced (F-H). S1P administration induced gene
13 ablated this S1P mediated gene induction (J) in contrast to JTE-013's stimulatory impact
centage of neurons with longest neurites (L) upon the different treatments. Each circle in
cate independent cultures analyzed. Statistical signiﬁcance was determined in relation to
Fig. 10. FTY720 activity requires the gene regulator SRF. Cerebellar neurons were electroporated with control siRNA (siCtr.) or siRNA targeting either SRF (siSrf) or CREB (siCreb).
Subsequently, neurons were incubated with DMSO or FTY720 for times indicated, followed by qPCR analysis for genes indicated (B-J) or by labeling growth cones for F-actin (red) and βIII
tubulin (green; K–P). (A) Immunoblotting experiments demonstrating efﬁcacy of siRNAs employed. Srf directed siRNA resulted in SRF downregulation, whereas siRNA directed against Creb
resulted in downregulation of total CREB and activated CREB (P-CREB). For quantiﬁcation, siCtr. levels were set to 1. (B–J) Upon SRF reduction, FTY720 mediated induction of gene
transcription of Egr1, Egr2, Acta, Cnn and Tagln but not of cFos, FosB, Tpm1a or Bdnfwas reduced. In contrast, induction of all genes by FTY720 was still possible upon CREB downregulation.
Numbers in bars in (B) indicate the number of independent cell cultures analyzed for each gene depicted in (B–J). (K) Growth cone of a DMSO treated neuron electroporated with control
siRNA. (K–K″) are individual channels depicting F-actin and βIII tubulin localization, respectively. (L) FTY720 application to the culture medium enhanced growth cone area and ﬁlopodia
number (arrows) of a neuron treated with control siRNA. (M) The growth cone of a neuron with SRF downregulation consisted of a slightly smaller growth cone area with fewer ﬁlopodia.
(N) FTY720 failed to enhance growth cone area and ﬁlopodia number of a neuron with SRF downregulation. (O and P) Quantiﬁcation of growth cone area (O; in μm2) or number of
ﬁlopodia/growth cone (P) for the different conditions. Each individual circle represents a single growth cone derived from one of at least three independent experiments. Statistical
signiﬁcance was calculated in relation to the DMSO treated control cultures (0 μM FTY720). The red lines indicate the mean values. Scale-bar (K–N) = 5 μm; (K′–N′; K″–N″) = 5 μm.
258 S. Anastasiadou, B. Knöll / Experimental Neurology 279 (2016) 243–260in vivo. Thus, our data suggest that duringMS therapy, FTY720might also
target neurons and might be beneﬁcial to enhance neuroprotective and
neurorestorative processes. In addition, our data suggest that FTY720
treatmentmight also be beneﬁcial for treatment of other neurodegenera-
tive diseases as well as central and peripheral nerve injuries.
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Fig. 11. Summary of FTY720's activity on neurons. FTY720 elicits in neurons an IEG
response connected to neuronal activity mediated gene transcription. In addition, FTY720
was able to induce an actin cytoskeletal gene response associated with altered growth
cone morphology, enhanced neurite growth and axon regeneration. FTY720 signaling
depends partially on S1PR1 and S1PR3 receptors. In contrast, S1PR2 receptors
appear to block FTY720 activity. FTY720's activity on the actin cytoskeleton is
mediated through a G12/13-RhoA-MRTF-A/SRF dependent signaling cascade.
FTY720 mediated IEG upregulation requires different signaling intermediates including
SRF and potentially SRF cofactors of the TCF family. The scheme also lists inhibitory
agents employed in this study.
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